SlideShare a Scribd company logo
1 of 30
Download to read offline
Navigating Multiple Clinical Trial
 Requirements for the US Market to
Ensure Compliance & Drive Exports
Presented at CPhI India Conference, Mumbai, December 2, 2011



              Dr. Bhaswat S. Chakraborty
          Senior Vice President & Chair
  R&D Core Committee, Cadila Pharmaceuticals Ltd.,
                  Ahmedabad
Content Guidelines
• Devising effective strategies to manage the US
  approval process and meet stringent global protocols
• Understanding the documentation requirements
• Overcoming the complexities around stability studies
  and batch designs to ensure a robust clinical trials
  procedure
• Examining best practice on conducting effective
  clinical trials in the US to establish a roadmap for
  success and swift future approval
Approval Process
• Complex – Main goal is to evaluate Safety, Efficacy
  & CMC decisively
• Data driven
   – Large volume, scientific, experimental
• Multi-disciplinary
   – Medical, chemistry, pharmaceutics, toxicology,
     pharmacology, biopharmaceutics, statistics,
     microbiology….
• Team work & sponsor-regulator communication
• Expertise and technicality required
Drug Development
• Drug development is ideally a logical, stepwise procedure in
  which information from small early studies is used to
  support and plan later larger, more definitive studies.
• To develop new drugs efficiently, it is essential to identify
  characteristics of the investigational medicine in the early
  stages.
• Initial trials provide an early evaluation of short-term safety
  and tolerability and can provide PK & PD information to
  choose a suitable dosage range and administration schedule
  for exploratory therapeutic trials.
• Later confirmatory studies are generally larger and longer
  and include a more diverse patient population.
Drug Development..
• Dose-response information should be obtained at all stages of
  development, from early tolerance studies, to studies of PD
  effects, to large efficacy studies (see ICH E4).
• Throughout development, new data may suggest the need for
  additional studies (part of an earlier phase).
   – For example, blood level data in a late trial may suggest a need for a
     drug-drug interaction study,
   – ADRs may suggest the need for further dose finding and/or additional
     nonclinical studies.
• In addition, to support a new marketing application approval
  for the same drug, e.g., for a new indication, pharmacokinetic
  or therapeutic exploratory studies are considered to be in
  Phase I or Phase II of development.
Source: Dr. R. Kane, USFDA
This matrix graph illustrates the relationship between the phases of development and
types of study by objective that may be conducted during each clinical development of
a new medicinal product.
The shaded circles show the types of study most usually conducted in a certain phase of
development, the open circles show certain types of study that may be conducted in that
phase of development but are less usual.
Each circle represents an individual study. To illustrate the development of a single
study, one circle is joined by a dotted line to an inset column that depicts the elements
and sequence of an individual study.
                                                           Federal Register (1997) 62, No. 242
Source: Dr. R. Kane, USFDA
Review Process
•   Once a new drug application is filed
     – an FDA review team evaluates whether the studies the sponsor
       submitted show that the drug is safe and effective for its proposed use
         • Team consists of medical doctors, chemists, statisticians, microbiologists,
           pharmacologists, and other experts
•   No drug is absolutely safe; all drugs have side effects
     – "Safe" in this sense above means that the benefits of the drug appear to
       outweigh the risks.
•   The review team
     – analyzes study results
     – looks for possible issues with the application
         • e.g., weaknesses of the study design or analyses
         • may agree with the sponsor's results and conclusions, or may need
           additional information to make a decision
•   Each reviewer prepares a written evaluation containing conclusions and
    recommendations about the application
•   These evaluations are then considered by team leaders, division directors,
    and office directors, depending on the type of application
                                                                                     10
The Quantity of Evidence to Support
               Effectiveness
•   Mainly three scenarios:
•   Effectiveness of a new use may be extrapolated entirely from existing
    efficacy studies.
•   A single adequate and well-controlled study of a specific new use can be
    supported by information from other related adequate and well-controlled
    studies
     – e.g., studies in other phases of a disease, in closely related diseases, of
        other conditions of use (different dose, duration of use, regimen), of
        different dosage forms, or of different endpoints.
     – a single multicenter study, without supporting information from other
        adequate and well-controlled studies
     – when a single study is used, there should be hardly any room for study
        imperfections or contradictory (non-supportive) information.
•   Two or more adequate and well-controlled studies.
Documentation of the Quality of Evidence
• Two main themes:
     1. Completeness of the documentation and
     2. The ability to access the primary study data and the original study-
         related records (e.g., subjects’ medical records, drug accountability
         records) for the purposes of verifying the data submitted as evidence.
•   These interrelated elements bear on a determination of whether a study is
    adequate and well-controlled.
•   In practice, to achieve a high level of documentation, studies supporting
    claims are ordinarily conducted in accordance with good clinical practices
    (GCPs).
•   Sponsors routinely monitor all clinical sites, and FDA routinely has access
    to the original clinical protocols, primary data, clinical site source
    documents for on-site audits, and complete study reports.
Quality by Design
•   Quality by Design is understanding the manufacturing process and
    identifying the key steps for obtaining and assuring a pre-defined final
    product quality.
•   FDA is constantly working to identify ways to improve the manufacturing
    process to ensure consistent product quality throughout the shelf life as
    well as to identify when contamination or other production failures may
    occur.
•   Improved quality by design will also lower product development and
    manufacturing costs by reducing the likelihood of production failures
    during a long run and by providing opportunities for continuous
    improvement.
•   As part of its Quality by Design effort, FDA is now working on three new
    areas to support increased manufacturing quality.
     – The first is a continuous processing where materials constantly flow in and out of
       equipment.
     – The second is the use of process analytical technology to monitor and control processes,
       as opposed to the current method of just testing products.
     – The third is the development of new statistical approaches to detect changes in process or
       product quality.
New Drug approved by USFDA in 2011




                        Incomplete list
Case Study Icatibant (FirazyrTM)
Icatibant




Icatibant (FirazyrTM) is a peptidomimetic drug consisting of ten amino acids, which is a selective
and specific antagonist of bradykinin B2 receptors. It has been approved by USFDA & EMA for
the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-
esterase-inhibitor deficiency).
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022150_firazyr_toc.cfm
• 34 USFDA officers, half of whom were
  reviewers took part in the approval process of
  this submission.
What does FDA Look for
           in Clinical Portion?
• FDA approves a drug application based on
  – Substantial evidence of efficacy & safety from
    “adequate and well-controlled investigations”
  – A valid comparison to a control
  – Quantitative assessment of the drug’s effect
     • (21 CFR 314.126.)



• The design and data quality of trials intended
  to support drug approval is very important
                                                     19
Proof of Efficacy & Safety
             Using a Valid Control
• The original NDA was submitted in October 2007, and a Not
  Approval action was taken in April 2008, because substantial
  evidence of efficacy was not demonstrated in two pivotal
  studies.
• The NDA included one placebo-controlled study that did not
  show efficacy.
• Another tranexamic acid (TA) active-controlled study that
  showed efficacy.
• Demonstration of efficacy in the TA active-controlled study
  was not considered adequate for approval because TA is not
  approved for the treatment of acute attacks of HAE.
• The sponsor has adequately addressed the efficacy deficiency
  with data submitted from a new placebo controlled study that
  shows efficacy.
FDA and Sponsor-FDA Meetings
• The Agency and the applicant had various
  interactions dating back to 2003.
  – teleconferences
• The FDA had Advisory Committee meetings.
• The FDA had many milestone review
  meetings
Validity of The Primary Efficacy Endpoint
           (often the Main Issue)
• Subsequent to the Not Approval action to the original NDA,
  the Sponsor met with the Division on December 15, 2008, to
  clarify the clinical deficiencies outlined.
• The Sponsor agreed to conduct a third, controlled study in
  patients with HAE to assess efficacy.
• Subsequently, the Sponsor submitted a request on February
  12, 2009, for a Special Protocol Assessment for the third
  study.
• Although no agreement was reached, the Division informed
  the Sponsor that a trial that was generally similar in design to
  the two previous studies would be acceptable for addressing
  the clinical deficiencies.
Novelty, Understanding the Mechanism of
Action and Differences from the Existing Drugs
  • At present Berinert and Kalbitor are approved in the US and
    elsewhere in the world for treatment of acute attacks of HAE.
     – Both of these products require administration by a healthcare
       professional and carry a risk of anaphylaxis.
  • Icatibant is a new molecular entity proposed for the treatment
    of acute attacks of HAE (hereditary angioedema) .
     – The putative mechanism of action of icatibant is inhibition of the
       bradykinin pathway by blocking the bradykinin type 2 receptor.
     – The bradykinin pathway is not directly responsible etiologically for
       HAE, but is thought to play an important role in causing the symptoms
       of HAE when the complement pathway is activated due to deficiency
       of C1 inhibitor (C1-INH) in these patients.
Chemistry, Manufacturing, and Controls
• The proposed expiry period of 18 months for drug product
  when stored at 2-25°C is supported by the submitted stability
  data.
• All manufacturing and testing sites related to this product have
  acceptable inspection status.
• Regarding syringe-needle compatibility, there were concerns
  raised by the Agency. These concerns, however, were not of a
  magnitude to preclude approval.
• Additional testing of the syringe needle compatibility that is
  statistically relevant may be pursued post-approval with the
  applicant since there are no safety or device performance
  issues identified so far.
Stability Data Required
• In general, 12-month real time stability data is
  recommended (ICH Guidance Q1A).
• Assignment of expiry dating period for the drug
  product may depend upon the real time stability data.
• And also on the totality of the NDA submission (e.g.,
  analytical, validation, impurity, etc.).
• These were the data asked for Icatibant.
Global Protocols and Reviews are
 Influenced by Experiences Elsewhere
• ….Worldwide post-marketing experience with Firazyr
  (Icatibant), which was approved in Europe three years ago and
  is now marketed in 37 countries overseas.
• As of June 30, 2011, a total of 2,044 injections have been
  administered during clinical trials and syringe/needle units
  have been sold, including for patient self-administration.
• To date, there have been no reports of device failure in the
  clinical trials, including a designated self-administration trial
  in 95 patients, and no post-marketing adverse events
  associated with device failure.
Nonclinical Pharmacology and
                Toxicology
• Nonclinical toxicology studies lasting 6 months in rats and 9
  months in dogs.
   – The primary toxicities were injection site irritation, testicular and
     uterine atrophy, and delay in sexual maturation.
   – Injection site irritation was not of concern because it can be monitored
     in humans.
• The reproductive toxicities observed in animals would not
  preclude approval given the severity of HAE disease and the
  fact that animals were dosed daily, whereas humans will
  receive icatibant intermittently.
• To address this finding further, a human clinical study to
  evaluate icatibant effects on reproductive hormones is
  currently ongoing.
Nonclinical Pharmacology and
                 Toxicology..
•   A complete genetic toxicology program was conducted, which was
    negative.
•   A complete battery of reproductive toxicology studies was conducted and
    the results support a Pregnancy Category C designation. Although there
    were no observed teratogenic effects, there were signs of embryotoxicity,
    and dose-related decreases in post-implantations and total number of live
    fetuses.
•   Additionally, icatibant prolonged gestation, resulting in spontaneous
    abortions and litter deaths.
•   The Sponsor has initiated carcinogenicity studies in rats and mice, which
    will be completed as post-marketing required (PMR) studies.
•   The Sponsor will also complete a post-marketing commitment study
    (PMC) to qualify impurities occurring at concentrations higher than
    defined thresholds.
Clinical Pharmacology and
              Biopharmaceutics
• The application is recommended for Approval from a Clinical
  Pharmacology perspective, and there are no outstanding
  clinical pharmacology issues.

• The application included results from a comprehensive clinical
  pharmacology program, which included studies to assess
  protein binding and metabolism in vitro, single- and multiple-
  dose pharmacokinetics, effect of hepatic impairment, the effect
  of renal impairment in hepatorenal syndrome, QTc effect, and
  effect on CYP540 isoenzymes.
Concluding Remarks
•   Options & factors for Sponsor’s strategies well considered
•   Therapeutic context
     –   NCE/NBE
     –   Orphan designation
     –   NDDS
     –   Generics
•   Approval tracks
     –   Unmet needs
     –   Fast track
     –   Priority review – 6 months
     –   One study (high quality)
     –   Standard review – 10 months
•   Protocol Assessments
•   Meetings with FDA
•   Thorough knowledge of data requirements, review process, milestones of
    the review process, how to respond to FDA queries, carry out additional
    (required studies), gain final approval and negotiate the post-marketing
    commitments
Thank you Very Much

More Related Content

What's hot

Principles of Drug Discovery and Development
Principles of Drug Discovery and DevelopmentPrinciples of Drug Discovery and Development
Principles of Drug Discovery and DevelopmentMANIKANDAN V
 
Features of clinical trials
Features of clinical trialsFeatures of clinical trials
Features of clinical trialsDRASHTI PATEL
 
Clinical studies – a primer
Clinical studies – a primerClinical studies – a primer
Clinical studies – a primerMoshe Ben Yitzhak
 
Clinical research basic things
Clinical research basic thingsClinical research basic things
Clinical research basic thingsSRIJIL SREEDHARAN
 
FDA 2013 Clinical Investigator Training Course: How do I put together an IND ...
FDA 2013 Clinical Investigator Training Course: How do I put together an IND ...FDA 2013 Clinical Investigator Training Course: How do I put together an IND ...
FDA 2013 Clinical Investigator Training Course: How do I put together an IND ...MedicReS
 
Clinical Trials Strategy: The Clinical Development Plan
Clinical Trials Strategy: The Clinical Development PlanClinical Trials Strategy: The Clinical Development Plan
Clinical Trials Strategy: The Clinical Development PlanMaRS Discovery District
 
Presentation working on clinical trials
Presentation working on clinical trialsPresentation working on clinical trials
Presentation working on clinical trialsSarah Henter
 
R&D GCP and Effective Site Management 011910
R&D GCP and Effective Site Management 011910R&D GCP and Effective Site Management 011910
R&D GCP and Effective Site Management 011910Myron Pyzyk
 
Clinical trials - ECRAN Project
Clinical trials - ECRAN ProjectClinical trials - ECRAN Project
Clinical trials - ECRAN ProjectScienzainrete
 
Clinical Research, A Basic Understanding...........
Clinical Research, A Basic Understanding...........Clinical Research, A Basic Understanding...........
Clinical Research, A Basic Understanding...........Jobin Kunjumon Vilapurathuu
 
Clinical Trials Introduction
Clinical Trials IntroductionClinical Trials Introduction
Clinical Trials Introductionbiinoida
 
1-Halt-it Protocol International v1.0 26nov12
1-Halt-it Protocol International v1.0 26nov121-Halt-it Protocol International v1.0 26nov12
1-Halt-it Protocol International v1.0 26nov12HALT-IT Trial
 
Basics of selenium
Basics of seleniumBasics of selenium
Basics of seleniumN H
 

What's hot (19)

Principles of Drug Discovery and Development
Principles of Drug Discovery and DevelopmentPrinciples of Drug Discovery and Development
Principles of Drug Discovery and Development
 
Features of clinical trials
Features of clinical trialsFeatures of clinical trials
Features of clinical trials
 
Clinical studies – a primer
Clinical studies – a primerClinical studies – a primer
Clinical studies – a primer
 
Turacoz - Clinical Study Report
Turacoz - Clinical Study ReportTuracoz - Clinical Study Report
Turacoz - Clinical Study Report
 
Clinical research basic things
Clinical research basic thingsClinical research basic things
Clinical research basic things
 
FDA 2013 Clinical Investigator Training Course: How do I put together an IND ...
FDA 2013 Clinical Investigator Training Course: How do I put together an IND ...FDA 2013 Clinical Investigator Training Course: How do I put together an IND ...
FDA 2013 Clinical Investigator Training Course: How do I put together an IND ...
 
Clinical Trials Strategy: The Clinical Development Plan
Clinical Trials Strategy: The Clinical Development PlanClinical Trials Strategy: The Clinical Development Plan
Clinical Trials Strategy: The Clinical Development Plan
 
Clinical trials
Clinical trialsClinical trials
Clinical trials
 
Clinical Study and Safety Reporting Activities Peivand Pirouzi 2011
Clinical Study and Safety Reporting Activities   Peivand Pirouzi 2011Clinical Study and Safety Reporting Activities   Peivand Pirouzi 2011
Clinical Study and Safety Reporting Activities Peivand Pirouzi 2011
 
3.clinical trials
3.clinical trials3.clinical trials
3.clinical trials
 
Presentation working on clinical trials
Presentation working on clinical trialsPresentation working on clinical trials
Presentation working on clinical trials
 
R&D GCP and Effective Site Management 011910
R&D GCP and Effective Site Management 011910R&D GCP and Effective Site Management 011910
R&D GCP and Effective Site Management 011910
 
Clinical trials - ECRAN Project
Clinical trials - ECRAN ProjectClinical trials - ECRAN Project
Clinical trials - ECRAN Project
 
Clinical Research, A Basic Understanding...........
Clinical Research, A Basic Understanding...........Clinical Research, A Basic Understanding...........
Clinical Research, A Basic Understanding...........
 
Clinical Trials Introduction
Clinical Trials IntroductionClinical Trials Introduction
Clinical Trials Introduction
 
SDTM Fnal Detail Training
SDTM Fnal Detail TrainingSDTM Fnal Detail Training
SDTM Fnal Detail Training
 
1-Halt-it Protocol International v1.0 26nov12
1-Halt-it Protocol International v1.0 26nov121-Halt-it Protocol International v1.0 26nov12
1-Halt-it Protocol International v1.0 26nov12
 
Components of a clinical study protocol
Components of a clinical study protocolComponents of a clinical study protocol
Components of a clinical study protocol
 
Basics of selenium
Basics of seleniumBasics of selenium
Basics of selenium
 

Viewers also liked

Changing medical device regulations in Europe and the U.S.
Changing medical device regulations in Europe and the U.S.Changing medical device regulations in Europe and the U.S.
Changing medical device regulations in Europe and the U.S.Maetrics
 
Globalization of Clinical Trials: Mutual acceptance of Medical Device data
Globalization of Clinical Trials: Mutual acceptance of Medical Device dataGlobalization of Clinical Trials: Mutual acceptance of Medical Device data
Globalization of Clinical Trials: Mutual acceptance of Medical Device dataAnnet Visscher
 
Medical Devices Postmarket Surveillance in Europe updated
Medical Devices Postmarket Surveillance in Europe updatedMedical Devices Postmarket Surveillance in Europe updated
Medical Devices Postmarket Surveillance in Europe updatedAnnet Visscher
 
EU Medical Device Regulation: Preparing for Disruptive (yet Incomplete) Regu...
EU Medical Device Regulation:  Preparing for Disruptive (yet Incomplete) Regu...EU Medical Device Regulation:  Preparing for Disruptive (yet Incomplete) Regu...
EU Medical Device Regulation: Preparing for Disruptive (yet Incomplete) Regu...YourEncoreInc
 
Premarket Clinical Evaluation under the EU MDR proposal
Premarket Clinical Evaluation under the EU MDR proposalPremarket Clinical Evaluation under the EU MDR proposal
Premarket Clinical Evaluation under the EU MDR proposalAnnet Visscher
 
FDA 2013 Clinical Investigator Training Course: CMC and Investigator Brochure...
FDA 2013 Clinical Investigator Training Course: CMC and Investigator Brochure...FDA 2013 Clinical Investigator Training Course: CMC and Investigator Brochure...
FDA 2013 Clinical Investigator Training Course: CMC and Investigator Brochure...MedicReS
 
Clinical Trial Requirements U.S. vs. EU Similarities and Differences
Clinical Trial Requirements U.S. vs. EU Similarities and DifferencesClinical Trial Requirements U.S. vs. EU Similarities and Differences
Clinical Trial Requirements U.S. vs. EU Similarities and DifferencesRETIRE
 

Viewers also liked (7)

Changing medical device regulations in Europe and the U.S.
Changing medical device regulations in Europe and the U.S.Changing medical device regulations in Europe and the U.S.
Changing medical device regulations in Europe and the U.S.
 
Globalization of Clinical Trials: Mutual acceptance of Medical Device data
Globalization of Clinical Trials: Mutual acceptance of Medical Device dataGlobalization of Clinical Trials: Mutual acceptance of Medical Device data
Globalization of Clinical Trials: Mutual acceptance of Medical Device data
 
Medical Devices Postmarket Surveillance in Europe updated
Medical Devices Postmarket Surveillance in Europe updatedMedical Devices Postmarket Surveillance in Europe updated
Medical Devices Postmarket Surveillance in Europe updated
 
EU Medical Device Regulation: Preparing for Disruptive (yet Incomplete) Regu...
EU Medical Device Regulation:  Preparing for Disruptive (yet Incomplete) Regu...EU Medical Device Regulation:  Preparing for Disruptive (yet Incomplete) Regu...
EU Medical Device Regulation: Preparing for Disruptive (yet Incomplete) Regu...
 
Premarket Clinical Evaluation under the EU MDR proposal
Premarket Clinical Evaluation under the EU MDR proposalPremarket Clinical Evaluation under the EU MDR proposal
Premarket Clinical Evaluation under the EU MDR proposal
 
FDA 2013 Clinical Investigator Training Course: CMC and Investigator Brochure...
FDA 2013 Clinical Investigator Training Course: CMC and Investigator Brochure...FDA 2013 Clinical Investigator Training Course: CMC and Investigator Brochure...
FDA 2013 Clinical Investigator Training Course: CMC and Investigator Brochure...
 
Clinical Trial Requirements U.S. vs. EU Similarities and Differences
Clinical Trial Requirements U.S. vs. EU Similarities and DifferencesClinical Trial Requirements U.S. vs. EU Similarities and Differences
Clinical Trial Requirements U.S. vs. EU Similarities and Differences
 

Similar to Final navigating multiple clinical trial requirements for the us

nda and phases of cr
nda and phases of crnda and phases of cr
nda and phases of crRohit K.
 
Pre-Clinical and Clinical Trials- Its design and Conduct, Risk Analysis, Qual...
Pre-Clinical and Clinical Trials- Its design and Conduct, Risk Analysis, Qual...Pre-Clinical and Clinical Trials- Its design and Conduct, Risk Analysis, Qual...
Pre-Clinical and Clinical Trials- Its design and Conduct, Risk Analysis, Qual...Gayatri R. Kachh
 
Phases 3,4 and 5 of clinical trials
Phases 3,4 and 5 of  clinical trialsPhases 3,4 and 5 of  clinical trials
Phases 3,4 and 5 of clinical trialsDrShrey Bhatia
 
Non clinical drug development. ppt
Non clinical drug development. pptNon clinical drug development. ppt
Non clinical drug development. pptPRABU12345678
 
Drug Discovery and Development.pptx
Drug Discovery and Development.pptxDrug Discovery and Development.pptx
Drug Discovery and Development.pptxVitthal Mane
 
planning and initiation.pptx
planning and initiation.pptxplanning and initiation.pptx
planning and initiation.pptxseeja2
 
Unit 1 Part 1Drug Development Process - Part 1.pptx
Unit 1  Part 1Drug Development Process - Part 1.pptxUnit 1  Part 1Drug Development Process - Part 1.pptx
Unit 1 Part 1Drug Development Process - Part 1.pptxDimple Marathe
 
Drug trail in cardiology i.tammi raju
Drug trail in cardiology i.tammi rajuDrug trail in cardiology i.tammi raju
Drug trail in cardiology i.tammi rajuTammiraju Iragavarapu
 
Veena Sanjay Katoriya
Veena Sanjay KatoriyaVeena Sanjay Katoriya
Veena Sanjay KatoriyaVEENA18
 
FDA applications in a nutshell
FDA applications in a nutshellFDA applications in a nutshell
FDA applications in a nutshellGwenHb
 
How Timely is Canada’s Medication Review and Approval Process?
How Timely is Canada’s Medication Review and Approval Process?How Timely is Canada’s Medication Review and Approval Process?
How Timely is Canada’s Medication Review and Approval Process?Canadian Cancer Survivor Network
 
Regulatory agencies
Regulatory agenciesRegulatory agencies
Regulatory agenciesUrmila Aswar
 
Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Aakashdeep Raval
 

Similar to Final navigating multiple clinical trial requirements for the us (20)

nda and phases of cr
nda and phases of crnda and phases of cr
nda and phases of cr
 
Pre-Clinical and Clinical Trials- Its design and Conduct, Risk Analysis, Qual...
Pre-Clinical and Clinical Trials- Its design and Conduct, Risk Analysis, Qual...Pre-Clinical and Clinical Trials- Its design and Conduct, Risk Analysis, Qual...
Pre-Clinical and Clinical Trials- Its design and Conduct, Risk Analysis, Qual...
 
Regulation reimbursement and evidence on NMT
Regulation reimbursement and evidence on NMTRegulation reimbursement and evidence on NMT
Regulation reimbursement and evidence on NMT
 
Clinical Trial Primer
Clinical Trial PrimerClinical Trial Primer
Clinical Trial Primer
 
Phases 3,4 and 5 of clinical trials
Phases 3,4 and 5 of  clinical trialsPhases 3,4 and 5 of  clinical trials
Phases 3,4 and 5 of clinical trials
 
Non clinical drug development. ppt
Non clinical drug development. pptNon clinical drug development. ppt
Non clinical drug development. ppt
 
INVESTIGATIONAL NEW DRUG (IND)
INVESTIGATIONAL NEW DRUG (IND) INVESTIGATIONAL NEW DRUG (IND)
INVESTIGATIONAL NEW DRUG (IND)
 
Investigational new drug
Investigational new drugInvestigational new drug
Investigational new drug
 
Drug Discovery and Development.pptx
Drug Discovery and Development.pptxDrug Discovery and Development.pptx
Drug Discovery and Development.pptx
 
planning and initiation.pptx
planning and initiation.pptxplanning and initiation.pptx
planning and initiation.pptx
 
Unit 1 Part 1Drug Development Process - Part 1.pptx
Unit 1  Part 1Drug Development Process - Part 1.pptxUnit 1  Part 1Drug Development Process - Part 1.pptx
Unit 1 Part 1Drug Development Process - Part 1.pptx
 
Phase 3
Phase 3Phase 3
Phase 3
 
Drug trail in cardiology i.tammi raju
Drug trail in cardiology i.tammi rajuDrug trail in cardiology i.tammi raju
Drug trail in cardiology i.tammi raju
 
Veena Sanjay Katoriya
Veena Sanjay KatoriyaVeena Sanjay Katoriya
Veena Sanjay Katoriya
 
FDA applications in a nutshell
FDA applications in a nutshellFDA applications in a nutshell
FDA applications in a nutshell
 
Nda.keerti
Nda.keertiNda.keerti
Nda.keerti
 
How Timely is Canada’s Medication Review and Approval Process?
How Timely is Canada’s Medication Review and Approval Process?How Timely is Canada’s Medication Review and Approval Process?
How Timely is Canada’s Medication Review and Approval Process?
 
Clinical trial
Clinical trialClinical trial
Clinical trial
 
Regulatory agencies
Regulatory agenciesRegulatory agencies
Regulatory agencies
 
Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.
 

More from Bhaswat Chakraborty

Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...
Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...
Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...Bhaswat Chakraborty
 
Statistical outliers in BE Studies DIA 12 april 2019
Statistical outliers in BE Studies DIA 12 april 2019Statistical outliers in BE Studies DIA 12 april 2019
Statistical outliers in BE Studies DIA 12 april 2019Bhaswat Chakraborty
 
Respiratory studies right approach in designs dia 11 april 2019 r
Respiratory studies right approach  in designs dia 11 april 2019 rRespiratory studies right approach  in designs dia 11 april 2019 r
Respiratory studies right approach in designs dia 11 april 2019 rBhaswat Chakraborty
 
Simplifying study designs and statistical models for new dose & dosage forms ...
Simplifying study designs and statistical models for new dose & dosage forms ...Simplifying study designs and statistical models for new dose & dosage forms ...
Simplifying study designs and statistical models for new dose & dosage forms ...Bhaswat Chakraborty
 
Equivalence approches for complex generics DIA 11 april 2019
Equivalence approches for complex generics DIA 11 april 2019 Equivalence approches for complex generics DIA 11 april 2019
Equivalence approches for complex generics DIA 11 april 2019 Bhaswat Chakraborty
 
Clinical Trial Requirements Medical Devices 27 dec2018
Clinical Trial Requirements Medical Devices 27 dec2018Clinical Trial Requirements Medical Devices 27 dec2018
Clinical Trial Requirements Medical Devices 27 dec2018Bhaswat Chakraborty
 
Writing scientific papers FINALDec 2018
Writing scientific papers FINALDec 2018Writing scientific papers FINALDec 2018
Writing scientific papers FINALDec 2018Bhaswat Chakraborty
 
Multidisc review of NDAs and BLAs nipicon 2018 Dr. Chakraborty
Multidisc review of NDAs and BLAs nipicon 2018 Dr. ChakrabortyMultidisc review of NDAs and BLAs nipicon 2018 Dr. Chakraborty
Multidisc review of NDAs and BLAs nipicon 2018 Dr. ChakrabortyBhaswat Chakraborty
 
Teaching by stories, anecdotes and historical facts sept 25 2018
Teaching by stories, anecdotes and historical facts sept 25 2018Teaching by stories, anecdotes and historical facts sept 25 2018
Teaching by stories, anecdotes and historical facts sept 25 2018Bhaswat Chakraborty
 
Orientation and Adaptation for Post-Graduate Pharmacy Programs
Orientation and Adaptation for Post-Graduate Pharmacy ProgramsOrientation and Adaptation for Post-Graduate Pharmacy Programs
Orientation and Adaptation for Post-Graduate Pharmacy ProgramsBhaswat Chakraborty
 
Plagiarism and Techniques to Avoid Plagiarism
Plagiarism and Techniques to Avoid PlagiarismPlagiarism and Techniques to Avoid Plagiarism
Plagiarism and Techniques to Avoid PlagiarismBhaswat Chakraborty
 
Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...
Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...
Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...Bhaswat Chakraborty
 
Pharmacists in Drug Discovery & Development
Pharmacists in Drug Discovery & Development Pharmacists in Drug Discovery & Development
Pharmacists in Drug Discovery & Development Bhaswat Chakraborty
 
Clinical Development of Biosimilars
Clinical Development of Biosimilars Clinical Development of Biosimilars
Clinical Development of Biosimilars Bhaswat Chakraborty
 
Challenges in Phase III Cancer Clinical Trials
Challenges in Phase III Cancer Clinical Trials Challenges in Phase III Cancer Clinical Trials
Challenges in Phase III Cancer Clinical Trials Bhaswat Chakraborty
 
Bioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug ProductsBioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug ProductsBhaswat Chakraborty
 
Bioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug ProductsBioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug ProductsBhaswat Chakraborty
 
Protein binding of drugs and screening of drugs by physicochemical properties
Protein binding of drugs  and screening of drugs by physicochemical propertiesProtein binding of drugs  and screening of drugs by physicochemical properties
Protein binding of drugs and screening of drugs by physicochemical propertiesBhaswat Chakraborty
 
Developing Protocols & Procedures for CT Data Integrity
Developing Protocols & Procedures for CT Data Integrity Developing Protocols & Procedures for CT Data Integrity
Developing Protocols & Procedures for CT Data Integrity Bhaswat Chakraborty
 

More from Bhaswat Chakraborty (20)

Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...
Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...
Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...
 
Statistical outliers in BE Studies DIA 12 april 2019
Statistical outliers in BE Studies DIA 12 april 2019Statistical outliers in BE Studies DIA 12 april 2019
Statistical outliers in BE Studies DIA 12 april 2019
 
Respiratory studies right approach in designs dia 11 april 2019 r
Respiratory studies right approach  in designs dia 11 april 2019 rRespiratory studies right approach  in designs dia 11 april 2019 r
Respiratory studies right approach in designs dia 11 april 2019 r
 
Simplifying study designs and statistical models for new dose & dosage forms ...
Simplifying study designs and statistical models for new dose & dosage forms ...Simplifying study designs and statistical models for new dose & dosage forms ...
Simplifying study designs and statistical models for new dose & dosage forms ...
 
Equivalence approches for complex generics DIA 11 april 2019
Equivalence approches for complex generics DIA 11 april 2019 Equivalence approches for complex generics DIA 11 april 2019
Equivalence approches for complex generics DIA 11 april 2019
 
Clinical Trial Requirements Medical Devices 27 dec2018
Clinical Trial Requirements Medical Devices 27 dec2018Clinical Trial Requirements Medical Devices 27 dec2018
Clinical Trial Requirements Medical Devices 27 dec2018
 
Writing scientific papers FINALDec 2018
Writing scientific papers FINALDec 2018Writing scientific papers FINALDec 2018
Writing scientific papers FINALDec 2018
 
Multidisc review of NDAs and BLAs nipicon 2018 Dr. Chakraborty
Multidisc review of NDAs and BLAs nipicon 2018 Dr. ChakrabortyMultidisc review of NDAs and BLAs nipicon 2018 Dr. Chakraborty
Multidisc review of NDAs and BLAs nipicon 2018 Dr. Chakraborty
 
Teaching by stories, anecdotes and historical facts sept 25 2018
Teaching by stories, anecdotes and historical facts sept 25 2018Teaching by stories, anecdotes and historical facts sept 25 2018
Teaching by stories, anecdotes and historical facts sept 25 2018
 
Orientation and Adaptation for Post-Graduate Pharmacy Programs
Orientation and Adaptation for Post-Graduate Pharmacy ProgramsOrientation and Adaptation for Post-Graduate Pharmacy Programs
Orientation and Adaptation for Post-Graduate Pharmacy Programs
 
Plagiarism and Techniques to Avoid Plagiarism
Plagiarism and Techniques to Avoid PlagiarismPlagiarism and Techniques to Avoid Plagiarism
Plagiarism and Techniques to Avoid Plagiarism
 
Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...
Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...
Best Practices to Risk Based Data Integrity at Data Integrity Conference, Lon...
 
Ethics in Pharmacy
Ethics in Pharmacy Ethics in Pharmacy
Ethics in Pharmacy
 
Pharmacists in Drug Discovery & Development
Pharmacists in Drug Discovery & Development Pharmacists in Drug Discovery & Development
Pharmacists in Drug Discovery & Development
 
Clinical Development of Biosimilars
Clinical Development of Biosimilars Clinical Development of Biosimilars
Clinical Development of Biosimilars
 
Challenges in Phase III Cancer Clinical Trials
Challenges in Phase III Cancer Clinical Trials Challenges in Phase III Cancer Clinical Trials
Challenges in Phase III Cancer Clinical Trials
 
Bioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug ProductsBioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug Products
 
Bioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug ProductsBioequivalence of Highly Variable Drug Products
Bioequivalence of Highly Variable Drug Products
 
Protein binding of drugs and screening of drugs by physicochemical properties
Protein binding of drugs  and screening of drugs by physicochemical propertiesProtein binding of drugs  and screening of drugs by physicochemical properties
Protein binding of drugs and screening of drugs by physicochemical properties
 
Developing Protocols & Procedures for CT Data Integrity
Developing Protocols & Procedures for CT Data Integrity Developing Protocols & Procedures for CT Data Integrity
Developing Protocols & Procedures for CT Data Integrity
 

Recently uploaded

Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 

Recently uploaded (20)

Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 

Final navigating multiple clinical trial requirements for the us

  • 1. Navigating Multiple Clinical Trial Requirements for the US Market to Ensure Compliance & Drive Exports Presented at CPhI India Conference, Mumbai, December 2, 2011 Dr. Bhaswat S. Chakraborty Senior Vice President & Chair R&D Core Committee, Cadila Pharmaceuticals Ltd., Ahmedabad
  • 2. Content Guidelines • Devising effective strategies to manage the US approval process and meet stringent global protocols • Understanding the documentation requirements • Overcoming the complexities around stability studies and batch designs to ensure a robust clinical trials procedure • Examining best practice on conducting effective clinical trials in the US to establish a roadmap for success and swift future approval
  • 3. Approval Process • Complex – Main goal is to evaluate Safety, Efficacy & CMC decisively • Data driven – Large volume, scientific, experimental • Multi-disciplinary – Medical, chemistry, pharmaceutics, toxicology, pharmacology, biopharmaceutics, statistics, microbiology…. • Team work & sponsor-regulator communication • Expertise and technicality required
  • 4. Drug Development • Drug development is ideally a logical, stepwise procedure in which information from small early studies is used to support and plan later larger, more definitive studies. • To develop new drugs efficiently, it is essential to identify characteristics of the investigational medicine in the early stages. • Initial trials provide an early evaluation of short-term safety and tolerability and can provide PK & PD information to choose a suitable dosage range and administration schedule for exploratory therapeutic trials. • Later confirmatory studies are generally larger and longer and include a more diverse patient population.
  • 5. Drug Development.. • Dose-response information should be obtained at all stages of development, from early tolerance studies, to studies of PD effects, to large efficacy studies (see ICH E4). • Throughout development, new data may suggest the need for additional studies (part of an earlier phase). – For example, blood level data in a late trial may suggest a need for a drug-drug interaction study, – ADRs may suggest the need for further dose finding and/or additional nonclinical studies. • In addition, to support a new marketing application approval for the same drug, e.g., for a new indication, pharmacokinetic or therapeutic exploratory studies are considered to be in Phase I or Phase II of development.
  • 6. Source: Dr. R. Kane, USFDA
  • 7. This matrix graph illustrates the relationship between the phases of development and types of study by objective that may be conducted during each clinical development of a new medicinal product. The shaded circles show the types of study most usually conducted in a certain phase of development, the open circles show certain types of study that may be conducted in that phase of development but are less usual. Each circle represents an individual study. To illustrate the development of a single study, one circle is joined by a dotted line to an inset column that depicts the elements and sequence of an individual study. Federal Register (1997) 62, No. 242
  • 8. Source: Dr. R. Kane, USFDA
  • 9. Review Process • Once a new drug application is filed – an FDA review team evaluates whether the studies the sponsor submitted show that the drug is safe and effective for its proposed use • Team consists of medical doctors, chemists, statisticians, microbiologists, pharmacologists, and other experts • No drug is absolutely safe; all drugs have side effects – "Safe" in this sense above means that the benefits of the drug appear to outweigh the risks. • The review team – analyzes study results – looks for possible issues with the application • e.g., weaknesses of the study design or analyses • may agree with the sponsor's results and conclusions, or may need additional information to make a decision • Each reviewer prepares a written evaluation containing conclusions and recommendations about the application • These evaluations are then considered by team leaders, division directors, and office directors, depending on the type of application 10
  • 10. The Quantity of Evidence to Support Effectiveness • Mainly three scenarios: • Effectiveness of a new use may be extrapolated entirely from existing efficacy studies. • A single adequate and well-controlled study of a specific new use can be supported by information from other related adequate and well-controlled studies – e.g., studies in other phases of a disease, in closely related diseases, of other conditions of use (different dose, duration of use, regimen), of different dosage forms, or of different endpoints. – a single multicenter study, without supporting information from other adequate and well-controlled studies – when a single study is used, there should be hardly any room for study imperfections or contradictory (non-supportive) information. • Two or more adequate and well-controlled studies.
  • 11. Documentation of the Quality of Evidence • Two main themes: 1. Completeness of the documentation and 2. The ability to access the primary study data and the original study- related records (e.g., subjects’ medical records, drug accountability records) for the purposes of verifying the data submitted as evidence. • These interrelated elements bear on a determination of whether a study is adequate and well-controlled. • In practice, to achieve a high level of documentation, studies supporting claims are ordinarily conducted in accordance with good clinical practices (GCPs). • Sponsors routinely monitor all clinical sites, and FDA routinely has access to the original clinical protocols, primary data, clinical site source documents for on-site audits, and complete study reports.
  • 12. Quality by Design • Quality by Design is understanding the manufacturing process and identifying the key steps for obtaining and assuring a pre-defined final product quality. • FDA is constantly working to identify ways to improve the manufacturing process to ensure consistent product quality throughout the shelf life as well as to identify when contamination or other production failures may occur. • Improved quality by design will also lower product development and manufacturing costs by reducing the likelihood of production failures during a long run and by providing opportunities for continuous improvement. • As part of its Quality by Design effort, FDA is now working on three new areas to support increased manufacturing quality. – The first is a continuous processing where materials constantly flow in and out of equipment. – The second is the use of process analytical technology to monitor and control processes, as opposed to the current method of just testing products. – The third is the development of new statistical approaches to detect changes in process or product quality.
  • 13. New Drug approved by USFDA in 2011 Incomplete list
  • 14. Case Study Icatibant (FirazyrTM)
  • 15. Icatibant Icatibant (FirazyrTM) is a peptidomimetic drug consisting of ten amino acids, which is a selective and specific antagonist of bradykinin B2 receptors. It has been approved by USFDA & EMA for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1- esterase-inhibitor deficiency).
  • 17. • 34 USFDA officers, half of whom were reviewers took part in the approval process of this submission.
  • 18. What does FDA Look for in Clinical Portion? • FDA approves a drug application based on – Substantial evidence of efficacy & safety from “adequate and well-controlled investigations” – A valid comparison to a control – Quantitative assessment of the drug’s effect • (21 CFR 314.126.) • The design and data quality of trials intended to support drug approval is very important 19
  • 19. Proof of Efficacy & Safety Using a Valid Control • The original NDA was submitted in October 2007, and a Not Approval action was taken in April 2008, because substantial evidence of efficacy was not demonstrated in two pivotal studies. • The NDA included one placebo-controlled study that did not show efficacy. • Another tranexamic acid (TA) active-controlled study that showed efficacy. • Demonstration of efficacy in the TA active-controlled study was not considered adequate for approval because TA is not approved for the treatment of acute attacks of HAE. • The sponsor has adequately addressed the efficacy deficiency with data submitted from a new placebo controlled study that shows efficacy.
  • 20. FDA and Sponsor-FDA Meetings • The Agency and the applicant had various interactions dating back to 2003. – teleconferences • The FDA had Advisory Committee meetings. • The FDA had many milestone review meetings
  • 21. Validity of The Primary Efficacy Endpoint (often the Main Issue) • Subsequent to the Not Approval action to the original NDA, the Sponsor met with the Division on December 15, 2008, to clarify the clinical deficiencies outlined. • The Sponsor agreed to conduct a third, controlled study in patients with HAE to assess efficacy. • Subsequently, the Sponsor submitted a request on February 12, 2009, for a Special Protocol Assessment for the third study. • Although no agreement was reached, the Division informed the Sponsor that a trial that was generally similar in design to the two previous studies would be acceptable for addressing the clinical deficiencies.
  • 22. Novelty, Understanding the Mechanism of Action and Differences from the Existing Drugs • At present Berinert and Kalbitor are approved in the US and elsewhere in the world for treatment of acute attacks of HAE. – Both of these products require administration by a healthcare professional and carry a risk of anaphylaxis. • Icatibant is a new molecular entity proposed for the treatment of acute attacks of HAE (hereditary angioedema) . – The putative mechanism of action of icatibant is inhibition of the bradykinin pathway by blocking the bradykinin type 2 receptor. – The bradykinin pathway is not directly responsible etiologically for HAE, but is thought to play an important role in causing the symptoms of HAE when the complement pathway is activated due to deficiency of C1 inhibitor (C1-INH) in these patients.
  • 23. Chemistry, Manufacturing, and Controls • The proposed expiry period of 18 months for drug product when stored at 2-25°C is supported by the submitted stability data. • All manufacturing and testing sites related to this product have acceptable inspection status. • Regarding syringe-needle compatibility, there were concerns raised by the Agency. These concerns, however, were not of a magnitude to preclude approval. • Additional testing of the syringe needle compatibility that is statistically relevant may be pursued post-approval with the applicant since there are no safety or device performance issues identified so far.
  • 24. Stability Data Required • In general, 12-month real time stability data is recommended (ICH Guidance Q1A). • Assignment of expiry dating period for the drug product may depend upon the real time stability data. • And also on the totality of the NDA submission (e.g., analytical, validation, impurity, etc.). • These were the data asked for Icatibant.
  • 25. Global Protocols and Reviews are Influenced by Experiences Elsewhere • ….Worldwide post-marketing experience with Firazyr (Icatibant), which was approved in Europe three years ago and is now marketed in 37 countries overseas. • As of June 30, 2011, a total of 2,044 injections have been administered during clinical trials and syringe/needle units have been sold, including for patient self-administration. • To date, there have been no reports of device failure in the clinical trials, including a designated self-administration trial in 95 patients, and no post-marketing adverse events associated with device failure.
  • 26. Nonclinical Pharmacology and Toxicology • Nonclinical toxicology studies lasting 6 months in rats and 9 months in dogs. – The primary toxicities were injection site irritation, testicular and uterine atrophy, and delay in sexual maturation. – Injection site irritation was not of concern because it can be monitored in humans. • The reproductive toxicities observed in animals would not preclude approval given the severity of HAE disease and the fact that animals were dosed daily, whereas humans will receive icatibant intermittently. • To address this finding further, a human clinical study to evaluate icatibant effects on reproductive hormones is currently ongoing.
  • 27. Nonclinical Pharmacology and Toxicology.. • A complete genetic toxicology program was conducted, which was negative. • A complete battery of reproductive toxicology studies was conducted and the results support a Pregnancy Category C designation. Although there were no observed teratogenic effects, there were signs of embryotoxicity, and dose-related decreases in post-implantations and total number of live fetuses. • Additionally, icatibant prolonged gestation, resulting in spontaneous abortions and litter deaths. • The Sponsor has initiated carcinogenicity studies in rats and mice, which will be completed as post-marketing required (PMR) studies. • The Sponsor will also complete a post-marketing commitment study (PMC) to qualify impurities occurring at concentrations higher than defined thresholds.
  • 28. Clinical Pharmacology and Biopharmaceutics • The application is recommended for Approval from a Clinical Pharmacology perspective, and there are no outstanding clinical pharmacology issues. • The application included results from a comprehensive clinical pharmacology program, which included studies to assess protein binding and metabolism in vitro, single- and multiple- dose pharmacokinetics, effect of hepatic impairment, the effect of renal impairment in hepatorenal syndrome, QTc effect, and effect on CYP540 isoenzymes.
  • 29. Concluding Remarks • Options & factors for Sponsor’s strategies well considered • Therapeutic context – NCE/NBE – Orphan designation – NDDS – Generics • Approval tracks – Unmet needs – Fast track – Priority review – 6 months – One study (high quality) – Standard review – 10 months • Protocol Assessments • Meetings with FDA • Thorough knowledge of data requirements, review process, milestones of the review process, how to respond to FDA queries, carry out additional (required studies), gain final approval and negotiate the post-marketing commitments